Clinical Trial: Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

U.S., May 19 -- ClinicalTrials.gov registry received information related to the study (NCT07594015) titled 'Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy' on May 11.

Brief Summary: The purpose of this study is to determine the efficacy and safety of Pembrolizumab in combination with Lenvatinib in recurrent, mismatch repair-proficient endometrial cancer after failure of first-line therapy with a platinum-based doublet chemotherapy and immunotherapy.

Study Start Date: June 01

Study Type: INTERVENTIONAL

Condition: Recurrent Endometrial Cancer

Intervention: DRUG: Pembrolizumab

Participants will receive 200mg of Pem...